Feb 21, 2018
Global Monoclonal Antibodies Market Hit $100 Billion in 2017: Report
Feb 17, 2018
AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting
Feb 07, 2018
Janssen Enters Into Worldwide Collaboration With Theravance Biopharma For Oral, Pan-JAK Inhibitor Drug Candidate For The Treatment Of Inflammatory Bowel Disease
Jan 05, 2018
Johnson & Johnson Innovation Champions Leading Edge Science with 15 New Collaborations with Potential to Impact Patients' Lives
Jan 04, 2018
Nuevolution to Receive License Fee Payment of USD 750,000
Dec 21, 2017
Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy
Nov 17, 2017
Market Access Impact: Rheumatoid Arthritis (EU5) 2016
Nov 06, 2017
STELARA® (ustekinumab) Shows Positive Results In Treatment Of Systemic Lupus Erythematosus In Phase 2 Trial
Nov 02, 2017
United States Product Portfolio for Immunology Drugs Market Report 2018
Oct 20, 2017
Janssen Receives Two U.S. FDA Approvals For SIMPONI ARIA® (golimumab) For The Treatment Of Adults With Active Psoriatic Arthritis Or Active Ankylosing Spondylitis
Oct 13, 2017
Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
Sep 22, 2017
Janssen Receives Complete Response Letter From U.S. FDA For Sirukumab Biologics License Application
Sep 14, 2017
Early Launch Metrics for Janssen's Tremfya May Lag Those of Lilly's Taltz at a Similar Post-Launch Period, but Signs Indicate the New IL-23 Inhibitor is Poised to Set a New Bar for Efficacy in Skin
Aug 29, 2017
US Gastroenterologists May Thwart Uptake of New Biosimilars Such as, Pfizer's Inflectra and Merck/Samsung Bioepis' Renflexis, by Choosing an Alternative TNF-Inhibitor, Such as AbbVie's Humira
Aug 02, 2017
FDA Advisory Committee Does Not Recommend Approval Of Sirukumab For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis
Jun 15, 2017
Johnson & Johnson Innovation Announces New Collaborations Advancing Ground-Breaking Biomedical Innovation Around the Globe
Jun 13, 2017
Pulmatrix Licenses Novel Drug Candidates from RespiVert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc.
May 30, 2017
Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. for Oral Interleukin-23 Receptor Antagonist Drug Candidate for the Treatment of Inflammatory Bowel Disease